{"company":{"id":3783024,"name":"Createrna","domain":"createrna.com","url":"https://alion.io/company/world-34"},"section":"news","answer":"Createrna: 18 headlines on record, 9 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"18"},{"label":"In 90 days","value":"9"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":13},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-09-17","kind":"Blog","title":"Join Us","url":"https://createrna.com/en/join-us/careers"},{"date":"2026-09-17","kind":"Blog","title":"Our Culture","url":"https://createrna.com/en/about-us/our-culture"},{"date":"2026-09-17","kind":"Blog","title":"Honor and Qualification","url":"https://createrna.com/en/about-us/about-lang-lai?tp=4"},{"date":"2026-09-17","kind":"Blog","title":"News Activity","url":"https://createrna.com/en/news-activity/news-center/news"},{"date":"2026-09-17","kind":"Blog","title":"Scientific R&D","url":"https://createrna.com/en/research-and-development/research-capabilities"},{"date":"2026-06-11","kind":"Blog","title":"China's First Domestically Developed Oral CFB Inhibitor: Createrna's Lanoracopan Hydrochloride Tablets Approved for Marketing","url":"https://createrna.com/en/news-activity/news-center/news/61.html"},{"date":"2026-05-12","kind":"Blog","title":"Createrna Receives IND Approval for Novel Class 1 Drug QR055453D Tablets for Idiopathic Pulmonary Fibrosis (IPF)","url":"https://createrna.com/en/news-activity/news-center/news/60.html"},{"date":"2026-02-13","kind":"Blog","title":"Createrna's MY008211A Tablets (Lanoracopan Hydrochloride) Achieve Primary Efficacy Endpoint in Phase III Trial in Complement Inhibitor-Naïve PNH Patients","url":"https://createrna.com/en/news-activity/news-center/news/59.html"},{"date":"2025-10-15","kind":"Blog","title":"Createrna's CFB Inhibitor MY008211A Tablets Granted Priority Review Designation and New Drug Application Accepted by China's NMPA","url":"https://createrna.com/en/news-activity/news-center/news/58.html"},{"date":"2025-08-04","kind":"News","title":"池尻大橋と三軒茶屋の間、三宿通り沿いに美味しさと芸術性を追求したクリエイティブな食の体験ができるレストラン、「CREATERNA ...","source":"news.infoseek.co.jp","url":"https://news.infoseek.co.jp/article/prtimes_000000001_000167021/"},{"date":"2025-03-14","kind":"Blog","title":"QR Science and Technology Donates RMB 100 Million to Huazhong University of Science and Technology for Medical Research Advancement","url":"https://createrna.com/en/news-activity/news-center/news/57.html"},{"date":"2024-11-28","kind":"Blog","title":"Createrna Announces Phase II Clinical Results of MY008211A in Treatment-Naïve PNH Patients at ASH 2024","url":"https://createrna.com/en/news-activity/news-center/news/56.html"},{"date":"2023-06-25","kind":"Press release","title":"Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan","url":"https://createrna.com/en/news-activity/news-center/news/54.html"}],"story":[{"title":"Raised a round Series A","url":"https://createrna.com/en/news-activity/news-center/news/54.html"},{"title":"Website went live first capture in the Wayback Machine","url":"https://web.archive.org/web/20210323080718/createrna.com"}],"as_of":"2026-11-17","cite":"Createrna, News. Alion, Nov 17, 2026. https://alion.io/company/world-34/news","html_url":"https://alion.io/company/world-34/news","json_url":"https://alion.io/company/world-34/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T21:47:23Z"}}